文献速递肝病消化道肿瘤与早癌

假小链双歧杆菌产生的乙酸盐抑制非酒精性脂肪性肝病相关肝细胞癌

Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2023-07-17

该研究在两种非酒精性脂肪性肝病相关肝细胞癌(NAFLD-HCC)小鼠模型中评估假小链双歧杆菌的作用,发现该菌在NAFLD-HCC小鼠中耗竭最显著,口服灌胃可显著抑制肿瘤形成(p < 0.01)。机制上,该菌产生的乙酸盐经门静脉到达肝脏,结合肝细胞GPR43,抑制IL-6/JAK1/STAT3通路,从而阻止NAFLD-HCC进展。

要点

  • 假小链双歧杆菌是NAFLD-HCC小鼠中耗竭最显著的细菌。
  • 口服假小链双歧杆菌在两种小鼠模型中显著抑制NAFLD-HCC形成(p < 0.01)。
  • 乙酸盐经门静脉入肝结合GPR43,抑制IL-6/JAK1/STAT3通路。

核心结论

  • 假小链双歧杆菌通过分泌抗肿瘤代谢物乙酸盐,经门静脉到达肝脏,保护小鼠免受NAFLD-HCC进展。
  • 假小链双歧杆菌有潜力作为预防NAFLD-HCC的益生菌。

研究设计与样本

  • 研究在两种NAFLD-HCC小鼠模型(二乙基亚硝胺+高脂/高胆固醇饮食,或+胆碱缺乏/高脂饮食)中评估假小链双歧杆菌的作用。
  • 使用无菌小鼠进行假小链双歧杆菌的代谢研究。
  • 收集小鼠粪便、门静脉和肝组织进行非靶向和靶向代谢组学分析。
  • 两种人NAFLD-HCC细胞系(HKCI2和HKCI10)与假小链双歧杆菌条件培养基(B.p CM)或候选代谢物共培养。

主要发现

  • 假小链双歧杆菌是NAFLD-HCC小鼠中耗竭最显著的细菌。
  • 口服灌胃假小链双歧杆菌在两种小鼠模型中显著抑制NAFLD-HCC形成(p < 0.01)。
  • B.p CM孵育NAFLD-HCC细胞显著抑制细胞增殖、抑制G1/S期转换并诱导凋亡。
  • 乙酸盐被鉴定为B.p CM中假小链双歧杆菌产生的关键代谢物,并在无菌小鼠中得到证实。
  • 乙酸盐在NAFLD-HCC细胞系中抑制细胞增殖并诱导凋亡,在体内抑制NAFLD-HCC肿瘤形成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recent studies have highlighted the role of the gut microbiota and their metabolites in non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC). We aimed to identify specific beneficial bacterial species that could be used prophylactically to prevent NAFLD-HCC. METHODS: The role of Bifidobacterium pseudolongum was assessed in two mouse models of NAFLD-HCC: diethylnitrosamine + a high-fat/high-cholesterol diet or + a choline-deficient/high-fat diet. Germ-free mice were used for the metabolic study of B. pseudolongum. Stool, portal vein and liver tissues were collected from mice for non-targeted and targeted metabolomic profiles. Two human NAFLD-HCC cell lines (HKCI2 and HKCI10) were co-cultured with B. pseudolongum-conditioned media (B.p CM) or candidate metabolites. RESULTS: B. pseudolongum was the top depleted bacterium in mice with NAFLD-HCC. Oral gavage of B. pseudolongum significantly suppressed NAFLD-HCC formation in two mouse models (p < 0.01). Incubation of NAFLD-HCC cells with B.p CM significantly suppressed cell proliferation, inhibited the G1/S phase transition and induced apoptosis. Acetate was identified as the critical metabolite generated from B. pseudolongum in B.p CM, an observation that was confirmed in germ-free mice. Acetate inhibited cell proliferation and induced cell apoptosis in NAFLD-HCC cell lines and suppressed NAFLD-HCC tumor formation in vivo. B. pseudolongum restored heathy gut microbiome composition and improved gut barrier function. Mechanistically, B. pseudolongum-generated acetate reached the liver via the portal vein and bound to GPR43 (G coupled-protein receptor 43) on hepatocytes. GPR43 activation suppressed the IL-6/JAK1/STAT3 signaling pathway, thereby preventing NAFLD-HCC progression. CONCLUSIONS: B. pseudolongum protected against NAFLD-HCC by secreting the anti-tumor metabolite acetate, which reached the liver via the portal vein. B. pseudolongum holds potential as a probiotic for the prevention of NAFLD-HCC. IMPACT AND IMPLICATIONS: Non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC) is an increasing healthcare burden worldwide. There is an urgent need to develop effective agents to prevent NAFLD-HCC progression. Herein, we show that the probiotic Bifidobacterium pseudolongum significantly suppressed NAFLD-HCC progression by secreting acetate, which bound to hepatic GPR43 (G coupled-protein receptor 43) via the gut-liver axis and suppressed the oncogenic IL-6/JAK1/STAT3 signaling pathway. Bifidobacterium pseudolongum holds potential as a novel probiotic for NAFLD-HCC prevention.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Song Q, Zhang X, Liu W, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023. PMID: 37459922. doi:10.1016/j.jhep.2023.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。